As the president and CEO of Versiti, Inc., Chris Miskel is excited to accelerate the pace of innovation in the years to come. “We pay as much attention to the number of lives impacted by our mission as we do to the revenue generated,” he said. “It’s why we start many of our meetings with mission moments – stories of the extraordinary things being done by our amazing teammates that have an immediate and tangible impact on the lives of those in our communities we call home.”
The mission of Versiti is personal and motivating, said Miskel. Versiti, Inc. is a world-class blood health organization with locations across the Midwest. Headquartered in Milwaukee, Versiti was formed with a mission of service to improve patient outcomes, advance the field of personalized medicine and strengthen the health of communities everywhere.
“At Versiti, we are literally saving the lives you love every single day as the fourth largest independent blood center in the United States,” said Miskel. “What attracted me to this wonderful organization is the same baseline strength that flows through our DNA today: excellence in science and medicine that dates back 76 years to our articles of incorporation.”
In six years as CEO at Versiti, Miskel has grown the company from $238 million in 2017 revenue to $398 million in 2022 by expanding Versiti’s reach with patients, customers and downers. He has also grown Versiti’s impact in the communities served, including allocation more than $40 million of income during this period to the Versiti Blood Research Institute Foundation for discovery research on blood disorders while expanding the workforce to better reflect the communities served.
In 2025, Miskel’s vision will come to life with a $65 million expansion of its blood research institute at the Milwaukee Regional Medical Center in Wauwatosa. This expansion will allow the company to hire up to 20 more principal research investigators and clinical researchers, which will help accelerate finding cures and better treatments for blood diseases and cancers.
“Through advocacy and community outreach, Chris continually aims to further establish Versiti as a trusted resource and agent of change for donors and patients in historically underserved communities of color, with the goal of eliminating racial, economic and social disparities in health care,” said his staff. “He combines strategic capability with a passion for people and believes that our employees are more effective when they can be themselves.”
His compassion, persistence and focus on community outreach is what has led Miskel to the Titan 100.
